Matthew M. Klein's most recent trade in ClearPoint Neuro Inc was a trade of 16,000 Common Stock done at an average price of $11.6 . Disclosure was reported to the exchange on May 21, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Sale of securities on an exchange or to another person at price $ 11.59 per share. | 21 May 2026 | 16,000 | 46,935 (0%) | 0% | 11.6 | 185,440 | Common Stock |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 12,820 | 12,820 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2026 | 12,417 | 0 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2026 | 12,417 | 62,935 (0%) | 0% | - | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2026 | 12,500 | 406,570 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 73.08 per share. | 13 May 2026 | 7,221 | 398,670 (0%) | 0% | 73.1 | 527,711 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 72.46 per share. | 13 May 2026 | 2,572 | 393,998 (0%) | 0% | 72.5 | 186,367 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 73.08 per share. | 13 May 2026 | 2,100 | 396,570 (0%) | 0% | 73.1 | 153,468 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 73.06 per share. | 13 May 2026 | 679 | 405,891 (0%) | 0% | 73.1 | 49,608 | Common Stock |
| AEVEX Corp Ordinary Shares | Matthew M. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 8,250 | 8,250 | - | 0 | Class A common stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 70.91 per share. | 21 Apr 2026 | 2,850 | 394,070 (0%) | 0% | 70.9 | 202,094 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2026 | 12,500 | 399,582 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 64.08 per share. | 11 Mar 2026 | 2,662 | 396,920 (0%) | 0% | 64.1 | 170,581 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 69.36 per share. | 18 Feb 2026 | 7,371 | 387,082 (0%) | 0% | 69.4 | 511,253 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 76.45 per share. | 08 Jan 2026 | 2,514 | 394,453 (0%) | 0% | 76.4 | 192,195 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 76.95 per share. | 06 Jan 2026 | 5,149 | 399,983 (0%) | 0% | 77.0 | 396,216 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 77.48 per share. | 06 Jan 2026 | 3,016 | 396,967 (0%) | 0% | 77.5 | 233,680 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 157,500 | 157,500 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 63,000 | 405,132 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew Klein B. | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 76.64 per share. | 30 Dec 2025 | 8,089 | 341,875 (0%) | 0% | 76.6 | 619,941 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 15,625 | 353,392 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 79.07 per share. | 01 Dec 2025 | 3,428 | 349,964 (0%) | 0% | 79.1 | 271,052 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2025 | 75,000 | 348,506 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 51.74 per share. | 01 Aug 2025 | 10,739 | 337,767 (0%) | 0% | 51.7 | 555,636 | Common Stock |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 12,417 | 12,417 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2025 | 21,093 | 50,518 (0%) | 0% | - | Common Stock | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2025 | 21,093 | 0 | - | - | Restricted Stock Units | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 48.74 per share. | 22 Apr 2025 | 2,804 | 273,234 (0%) | 0% | 48.7 | 136,656 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 50.10 per share. | 19 Feb 2025 | 3,897 | 279,933 (0%) | 0% | 50.1 | 195,224 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 50.12 per share. | 19 Feb 2025 | 3,895 | 276,038 (0%) | 0% | 50.1 | 195,233 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 44.50 per share. | 07 Jan 2025 | 2,402 | 283,830 (0%) | 0% | 44.5 | 106,889 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 45.34 per share. | 07 Jan 2025 | 2,142 | 286,232 (0%) | 0% | 45.3 | 97,118 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 70,000 | 288,374 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 45.16 per share. | 31 Dec 2024 | 8,279 | 217,528 (0%) | 0% | 45.2 | 373,880 | Common Stock |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 21,093 | 21,093 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 17,153 | 0 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 17,153 | 29,425 (0%) | 0% | - | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 24.89 per share. | 19 Apr 2024 | 3,361 | 225,807 (0%) | 0% | 24.9 | 83,669 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 25.13 per share. | 17 Apr 2024 | 1,307 | 229,168 (0%) | 0% | 25.1 | 32,851 | Common Stock |
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 04 Mar 2024 | 3,277 | 90,731 (0%) | 0% | 5.8 | 18,876 | Common Stock | |
| PTC Therapeutics Inc | Klein Matthew B. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 70,000 | 230,475 (0%) | 0% | 0 | Common Stock | |
| Spirit Airlines Inc | Klein Hilary Matthew | EVP, CCO | 30 Jan 2024 | 2,276 | 87,454 (0%) | 0% | 6.4 | 14,544 | Common Stock | |
| PTC Therapeutics Inc | Klein Matthew B. | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 29.01 per share. | 08 Jan 2024 | 5,443 | 160,475 (0%) | 0% | 29.0 | 157,928 | Common Stock |
| PTC Therapeutics Inc | B. Matthew Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 28.64 per share. | 08 Jan 2024 | 2,237 | 165,918 (0%) | 0% | 28.6 | 64,068 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 27.15 per share. | 05 Jan 2024 | 10,107 | 168,155 (0%) | 0% | 27.1 | 274,393 | Common Stock |
| PTC Therapeutics Inc | Matthew Klein B. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2023 | 75,000 | 177,961 (0%) | 0% | 0 | Common Stock | |
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 28 Dec 2023 | 4,300 | 91,258 (0%) | 0% | 16.4 | 70,520 | Common Stock | |
| Spirit Airlines Inc | Klein Hilary Matthew | EVP, CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.40 per share. | 28 Dec 2023 | 2,790 | 84,168 (0%) | 0% | 16.4 | 45,756 | Common Stock |
| Spirit Airlines Inc | Hilary Matthew Klein | EVP, CCO | 28 Dec 2023 | 1,528 | 89,730 (0%) | 0% | 7.9 | 12,102 | Common Stock | |
| Spirit Airlines Inc | Klein Matthew Hilary | EVP, CCO | 27 Dec 2023 | 2,605 | 86,958 (0%) | 0% | 16.5 | 42,878 | Common Stock | |
| Spirit Airlines Inc | Matthew Klein Hilary | EVP, CCO | 18 Dec 2023 | 1,286 | 89,563 (0%) | 0% | 16.0 | 20,615 | Common Stock | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 17,153 | 17,153 | - | - | Restricted Stock Units | |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2023 | 26,000 | 103,856 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 52.04 per share. | 18 Apr 2023 | 1,211 | 102,645 (0%) | 0% | 52.0 | 63,025 | Common Stock |
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 06 Mar 2023 | 1,108 | 90,849 (0%) | 0% | 16.4 | 18,127 | Common Stock | |
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 30 Jan 2023 | 25,367 | 89,741 (0%) | 0% | 0 | Common Stock | ||
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 13 Jan 2023 | 3,221 | 64,374 (0%) | 0% | 20.7 | 66,546 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 42.93 per share. | 10 Jan 2023 | 2,273 | 80,100 (0%) | 0% | 42.9 | 97,586 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 44.36 per share. | 10 Jan 2023 | 2,244 | 77,856 (0%) | 0% | 44.4 | 99,543 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 41.66 per share. | 09 Jan 2023 | 731 | 82,373 (0%) | 0% | 41.7 | 30,451 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 26,000 | 83,104 (0%) | 0% | 0 | Common Stock | |
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 29 Dec 2022 | 2,218 | 67,595 (0%) | 0% | 19.6 | 43,562 | Common Stock | |
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 27 Dec 2022 | 924 | 65,377 (0%) | 0% | 19.4 | 17,898 | Common Stock | |
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 16 Dec 2022 | 796 | 66,301 (0%) | 0% | 20.0 | 15,928 | Common Stock | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 9,269 | 12,272 (0%) | 0% | 0 | Common Stock | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 6,179 | 6,179 | - | - | Stock Options (right to buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 42.52 per share. | 19 Apr 2022 | 897 | 56,564 (0%) | 0% | 42.5 | 38,136 | Common Stock |
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 07 Mar 2022 | 1,009 | 67,097 (0%) | 0% | 0 | Common Stock | ||
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 18 Jan 2022 | 255 | 66,088 (0%) | 0% | 23.0 | 5,862 | Common Stock | |
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 14 Jan 2022 | 712 | 66,343 (0%) | 0% | 23.3 | 16,582 | Common Stock | |
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 13 Jan 2022 | 15,454 | 67,055 (0%) | 0% | 0 | Common Stock | ||
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 13 Jan 2022 | 1,844 | 51,601 (0%) | 0% | 23.8 | 43,850 | Common Stock | |
| Spirit Airlines Inc | Matthew Hilary Klein | EVP, CCO | 11 Jan 2022 | 255 | 53,445 (0%) | 0% | 22.8 | 5,814 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 52,500 | 52,500 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 21,000 | 37,461 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 20,000 | 57,461 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 38.53 per share. | 07 Jan 2022 | 775 | 16,461 (0%) | 0% | 38.5 | 29,857 | Common Stock |